Diverse and targetable kinase alterations drive histiocytic neoplasms

Cancer Discovery

Volumn 6, Issue 2, 2016, Pages 154-165

  Diamond, Eli L ^a   Durham, Benjamin H ^a   Haroche, Julien ^b   Yao, Zhan ^a   Ma, Jing ^c   Parikh, Sameer A ^d   Wang, Zhaoming ^c   Choi, John ^c   Kim, Eunhee ^a   Cohen Aubart, Fleur ^b   Lee, Stanley Chun Wei ^a   Gao, Yijun ^a   Micol, Jean Baptiste ^a   Campbell, Patrick ^c   Walsh, Michael P ^c   Sylvester, Brooke ^a   Dolgalev, Igor ^e   Aminova, Olga ^e   Heguy, Adriana ^e   Zappile, Paul ^e   Nakitandwe, Joy ^c   Ganzel, Chezi ^f   Dalton, James D ^c   Ellison, David W ^c   Estrada Veras, Juvianee ^g   Lacouture, Mario ^a   Gahl, William A ^g   Stephens, Philip J ^h   Miller, Vincent A ^h   Ross, Jeffrey S ^h   Ali, Siraj M ^h   Briggs, Samuel R ^a   Fasan, Omotayo ⁱ   Block, Jared ^j   Heritier, Sebastien ^k,l   Donadieu, Jean ^k,l   Solit, David B ^a   Hyman, David M ^a   Baselga, Jose ^a   Janku, Filip ^m   Taylor, Barry S ^a   Park, Christopher Y ^a   Amoura, Zahir ^b   Dogan, Ahmet ^a   Emile, Jean Francois ^j,n   Rosen, Neal ^a   Gruber, Tanja A ^c   Abdel Wahab, Omar ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f SHAARE ZEDEK MEDICAL CENTER   (Israel)

^g NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^h FOUNDATION MEDICINE   (United States)

ⁱ LEVINE CANCER INSTITUTE   (United States)

^j Carolinas Pathology Group   (United States)

^k ARMAND TROUSSEAU HOSPITAL   (France)

^l LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; COBIMETINIB; CRIZOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; SORAFENIB; TRAMETINIB; VEMURAFENIB; BRAF PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; ERDHEIM CHESTER DISEASE; GENE FUSION; GENE MUTATION; GENOME ANALYSIS; HISTIOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; LANGERHANS CELL HISTIOCYTOSIS; NEXT GENERATION SEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SERIAL ANALYSIS OF GENE EXPRESSION; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; HISTIOCYTOSIS, LANGERHANS-CELL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; MUTATION; PROCEDURES; SIGNAL TRANSDUCTION;

GENE EXPRESSION PROFILING; HISTIOCYTOSIS, LANGERHANS-CELL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; SEQUENCE ANALYSIS, DNA;

EID: 84957056573     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0913     Document Type: Article

References (47)

1. Jaffe R, Pileri SA, Facchetti F, Jones DM, Jaffe ES. Histiocytic and dendritic cell neoplasms, Introduction. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: WHO Press; 2008.p. 354–5.
2. Badalian-Very G, Vergilio J-A, Degar B, MacConaill L, Brandner B, Calicchio M, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116: 1919–23.
3. V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014; 211: 669–83.
4. Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120: 2700–3.
5. V600E mutation. Blood 2013; 121: 1495–500.
6. Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Toledano D, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim–Chester disease. J Clin Oncol 2015; 33: 411–8.
7. V600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov 2015; 5: 64–71.
8. Heritier S, Jehanne M, Leverger G, Emile JF, Alvarez JC, Haroche J, et al. Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis. JAMA Oncol 2015; 1: 836–8.
9. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 2014; 124: 483–92.
10. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014; 124: 3007–15.
11. V600E- negative Langerhans cell histiocytosis. Blood 2014; 124: 1655–8.
12. Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovee JV, Patel B, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 2015; 54: 361–8.
13. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488–98.
14. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477–87.
15. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Agerelated mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472–8.
16. Emile JF, Diamond EL, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, et al. Recurrent RAS and PIK3CA mutations in Erdheim–Chester disease. Blood 2014; 124: 3016–9.
17. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pfl ueger D, Ramnarayanan K, Shankar S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16: 793–8.
18. H utchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 2013; 19: 6696–702.
19. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013; 110: 5957–62.
20. Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov 2014; 4: 1398–405.
21. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B–ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143–9.
22. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014; 5: 3116.
23. Allen CE, Li L, Peters TL, Leung HC, Yu A, Man TK, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010; 184: 4557–67.
24. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol 2012; 13: 888–99.
25. Baldus CD, Tanner SM, Kusewitt DF, Liyanarachchi S, Choi C, Caligiuri MA, et al. BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol 2003; 31: 1051–6.
26. Perry SS, Zhao Y, Nie L, Cochrane SW, Huang Z, Sun XH. Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. Blood 2007; 110: 2351–60.
27. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 2012; 13: 1118–28.
28. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest 2014; 124: 1582–6.
29. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167–77.
30. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non–small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014; 15: 1119–28.
31. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015; 5: 25–34.
32. Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovee JV, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 2014; 123: 3152–5.
33. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015; 373: 726–36.
34. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 4456–62.
35. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 2450–7.
36. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012; 18: 555–67.
37. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485: 502–6.
38. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107–20.
39. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519–25.
40. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157–63.
41. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 2012; 22: 683–97.
42. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol 2013; 31: 46–53.
43. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28: 511–5.
44. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545–50.
45. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering–integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015; 17: 251–64.
46. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023–31.
47. McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H, Stephens J, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep 2015; 10: 1239–45.